Correction to “Induction of Resistance to Neurotrophic Tropomyosin‐Receptor Kinase Inhibitors by HMGCS2 via a Mevalonate Pathway”

Documenti analoghi

• Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway
  di: Yasuhiro Kato, et al.
  Pubblicazione: (2024)
• Tropomyosin 3 Gene Fusions in Cancers: From Mechanisms to Treatments—A Comprehensive Review
  di: Anjie Chen, et al.
  Pubblicazione: (2025)
• The Multi‐Kinase Inhibitor GZD824 (Olverembatinib) Shows Pre‐Clinical Efficacy in Endometrial Cancer
  di: Dongli Liu, et al.
  Pubblicazione: (2024)
• Assessment of Treatment Outcome in Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors: Insight From a Resource Limited Setting
  di: Wude Yewondwosen Awlachew, et al.
  Pubblicazione: (2025)
• Multi‐Targeted Kinase Inhibitor Therapy in Pediatric Bone and Soft Tissue Sarcoma Patients—A Single Centre Experience
  di: Anna Mohás, et al.
  Pubblicazione: (2025)